Tf-RVG Coated PLGA Nanoparticles for Brain-Targeted Risperidone Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of reduced protein diet (RPD) medications face challenges in effectively targeting and sustaining delivery to the brain due to the blood-brain barrier, resulting in variable absorption and higher systemic side effects, with existing solutions failing to provide adequate brain penetrance and prolonged action.
Innovation Solution
A polymeric-based nanoparticle composition coated with Transferrin (Tf) and Rabies Virus Glycoprotein (RVG) is developed, utilizing a process that includes dissolving RPD and lipid in isopropyl alcohol, adding an aqueous surfactant solution, and conjugating Tf and RVG to PLGA nanoparticles to enhance brain penetrance and duration of action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RPD is administered orally to treat psychotic illnesses, then the medication can control psychotic symptoms, but the drug undergoes substantial first-pass metabolism and has variable bioavailability (70% CV: 25%), resulting in inconsistent therapeutic effect
Solution Approach 1:
The patent uses nanoparticles as an intermediary carrier system to transport RPD across the blood-brain barrier. The nanoparticle formulation protects the drug from first-pass metabolism by encapsulating it, and the transferrin coating enables targeted delivery to the brain through receptor-mediated transport, thereby improving bioavailability and reducing metabolic degradation
Solution Approach 2:
The patent changes the physical and chemical parameters of RPD by formulating it into nanoparticles with specific size ranges (50-200 nm) and surface coatings. This parameter change transforms the drug from a conventional oral formulation subject to first-pass metabolism into a nanoparticle system that can exploit BBB transport mechanisms, achieving more reliable and consistent brain delivery
2Reliability
If RPD is delivered to achieve therapeutic effect, then psychotic symptoms can be controlled, but the drug has short half-life (less than 3 hours), requiring frequent administration and reducing patient compliance
Solution Approach 1:
The patent applies preliminary action by pre-coating nanoparticles with transferrin before drug encapsulation. This pre-prepared nanoparticle system is designed to exploit the BBB's transferrin receptor transport mechanism, enabling the drug to achieve prolonged circulation time and sustained brain delivery without requiring frequent re-administration
Solution Approach 2:
The nanoparticle formulation provides continuous drug delivery to the brain by utilizing the sustained release properties of the nanoparticle matrix. The controlled release mechanism maintains therapeutic drug levels at the target site over an extended period, converting the short half-life limitation into a sustained action profile
3Reliability
If RPD is administered at higher doses to ensure therapeutic effect, then psychotic symptoms can be controlled, but extrapyramidal side effects (EPS) increase, requiring the smallest effective dosage
Solution Approach 1:
The patent applies local quality by targeting the drug delivery specifically to the brain through transferrin-coated nanoparticles. This localized delivery ensures that the therapeutic effect is concentrated at the target site (brain) while minimizing systemic exposure, thereby controlling psychotic symptoms with lower doses and reducing extrapyramidal side effects
Solution Approach 2:
The nanoparticle system acts as an intermediary that selectively transports RPD across the blood-brain barrier. This mediator enables the drug to reach the brain efficiently at lower doses, avoiding the need for high systemic dosing that would cause EPS, while still achieving the desired therapeutic effect in the central nervous system
4Ease of operation
If conventional formulations are used to deliver RPD, then the medication can be administered easily, but the drug does not readily passively cross the BBB, resulting in poor brain penetrance
Solution Approach 1:
The patent uses transferrin as an intermediary molecule that mediates the transport of RPD across the blood-brain barrier. The transferrin coating on nanoparticles enables the drug to exploit the BBB's natural transferrin receptor-mediated transport system, converting passive administration into active targeted delivery without requiring invasive procedures
Solution Approach 2:
The patent changes the surface properties of the nanoparticle by coating with transferrin, which fundamentally alters the drug's interaction with the BBB. This parameter change transforms the nanoparticle from a non-penetrating carrier into a targeted delivery system that actively exploits receptor-mediated transport mechanisms to achieve reliable brain penetrance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticle composition achieves better brain penetrance, prolonged action, reduced side effects, and increased bioavailability, leading to improved treatment efficacy and patient compliance by providing targeted and sustained drug delivery to the brain.
Implementation Method 1
Endogenous active transport mechanisms, such as receptor-mediated transport, are an appealing method for delivering medications to specific areas of the brain (RMT). Tf-conjugated drug delivery systems (nanoparticles, liposomes, and micelles) can enhance drug transport across the BBB.
Implementation Method 2
adding 45-100 wt % of Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 45-100 wt % of N-Hydroxysulfosuccinimide (NHS), which included activating the carboxylic acid terminal groups and conjugating Tf and RVG to RPD's PLGA nanoparticles
Implementation Method 3
the RPD's half-life can be extended because to the PLGA nanoparticles' sustained release capabilities, which can lower administration frequency and boost patient compliance
Implementation Method 4
smaller nanoparticles (less than 100 nm) could improve our formulation's ability to penetrate the BBB and enter the brain since size affects brain penetrance
Data Source
AI summary
The present invention generally relates to a process for preparing polymeric-based nanoparticle of RPD coated with Tf and RVG comprises dissolving 1-12 wt % of RPD and 8-96 wt % of lipid in isopropyl alcohol (IPA) and heating the solution to 70° C. to create the organic phase; adding prepared organic solution to the 0-2 wt % of aqueous surfactant solution using a syringe at 70° C. temperature; swirling the obtained solution at 1000 rpm on a high speed homogenizer for 15 minutes after the solvent is evaporated using a magnetic stirrer to create the SLNs dispersion; and adding 45-100 wt % of Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 45-100 wt % of N-Hydroxysulfosuccinimide (NHS), which included activating the carboxylic acid terminal groups and conjugating Tf and RVG to RPD's PLGA nanoparticles.